Dublin, April 07, 2026 (GLOBE NEWSWIRE) — The “Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The cell-free tumor DNA detection market is set to experience significant growth, expanding from $2.58 billion in 2025 to $3.02 billion in 2026 at a CAGR of 17.2%. This growth trajectory underscores the increasing prevalence of cancer, advances in molecular diagnostics, and heightened demand for non-invasive testing options, particularly adoption of PCR and NGS techniques.
Fast forward to 2030, the market is forecasted to reach $5.64 billion with a CAGR of 16.9%, driven by the proliferation of precision medicine, technological innovations in ctDNA analysis, integration with AI-based diagnostics, and burgeoning healthcare investments in emerging economies. Notable trends include the integration of genomic data platforms, real-time tumor monitoring, and innovative ctDNA detection technologies.
Personalized medicine is a key driver of market growth, leveraging the precision of genomics to tailor treatments based on individual genetic profiles. This approach, facilitated by cell-free tumor DNA detection, enables non-invasive, real-time insights into patient-specific tumor characteristics, leading to customized therapies, improved tracking of therapeutic responses, and early identification of disease recurrence. Highlighting this trend, the Personalized Medicine Coalition reported a rise in FDA-approved personalized medicines, from 12 in 2022 to 26 in 2023, illustrating growing demand in this sector.
Industry leaders are enhancing DNA detection technologies, exemplified by Twist Bioscience’s introduction of the cfDNA Library Preparation Kit in February 2024. This product improves the sensitivity and accuracy of liquid biopsy applications, addressing challenges with low-input and degraded DNA samples, thereby boosting the reliability and efficacy of early cancer detection and treatment monitoring.
Additionally, corporate consolidation is intensifying with Quest Diagnostics’ acquisition of Haystack Oncology in April 2023, aimed at expanding its oncology portfolio through advanced liquid biopsy technology from Haystack. This move aligns with industry efforts to refine precision in cancer detection and support tailored treatment approaches.
Dominant firms in this market include F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., Labcorp Holdings Inc., Illumina Inc., and many others, actively contributing to advancements and growth within the sector. North America leads the market, while Asia-Pacific is poised for rapid expansion. Tariffs, meanwhile, impact operational costs but also drive local innovation in cost-effective ctDNA technologies.
Reasons to Purchase:
- Comprehend the market with a global perspective, spanning 16 geographies.
- Evaluate macro factors like geopolitical conflicts, trade policies, inflation, regulatory shifts, and their market impact.
- Develop regional strategies using localized data and analysis.
- Spot investment-worthy growth segments.
- Gain a competitive edge with forecast data and market-shaping drivers.
- Understand end-user dynamics for better customer insights.
- Benchmark against competitors using metrics of market share, innovation, and brand stature.
- Assess market potential through total addressable market analysis and market attractiveness scoring.
- Utilize this report for internal and client presentations with credible data.
- Receive up-to-date data alongside an Excel sheet for enhanced data manipulation.
- Access data in an Excel dashboard format for comprehensive insights.
Report Scope:
- Markets Covered:
- By Technology: PCR, NGS, dPCR
- By Source: Plasma, Serum, Urine
- By Application: Oncology, Non-Invasive Prenatal Testing, Transplantation
- By End-User: Hospitals, Laboratories, Academic Institutes
- Geographic Coverage: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
- Regions: Asia-Pacific, Southeast Asia, Western and Eastern Europe, North and South America, Middle East, Africa
- Time Series: Historical data and forecasts covering 15 years
Key Attributes
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026-2030 |
| Estimated Market Value (USD) in 2026 | $3.02 Billion |
| Forecasted Market Value (USD) by 2030 | $5.64 Billion |
| Compound Annual Growth Rate | 16.9% |
| Regions Covered | Global |
The companies featured in this Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection market report include:
- F. Hoffmann-La Roche AG
- Thermo Fisher Scientific Inc.
- Labcorp Holdings Inc.
- Illumina Inc.
- Sysmex Inostics Inc.
- Bio-Rad Laboratories Inc.
- QIAGEN N.V.
- Natera Inc.
- Guardant Health Inc.
- Invitae Corporation
- Foundation Medicine Inc
- Adaptive Biotechnologies Corporation
- Freenome Holdings Inc.
- Grail Inc.
- Biodesix Inc
- Personal Genome Diagnostics Inc.
- Agena Bioscience Inc.
- Menarini Silicon Biosystems SpA
- Exosome Diagnostics Inc.
- Lucence Health Inc.
For more information about this report visit https://www.researchandmarkets.com/r/sc7m21
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Cell Free Tumor Deoxyribonucleic Acid (DNA) Detection Market
